MARKET

IRWD

IRWD

Ironwood Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.28
+0.12
+0.91%
Opening 15:13 07/30 EDT
OPEN
13.20
PREV CLOSE
13.16
HIGH
13.46
LOW
13.14
VOLUME
923.85K
TURNOVER
--
52 WEEK HIGH
13.65
52 WEEK LOW
8.63
MARKET CAP
2.15B
P/E (TTM)
15.00
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 7h ago
Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 1d ago
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
Zacks.com · 1d ago
Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?
Zacks.com · 1d ago
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28)
Benzinga · 1d ago
What's in Store for Perrigo (PRGO) This Earnings Season?
Zacks.com · 2d ago
Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?
Zacks.com · 2d ago
Gilead (GILD) to Report Q2 Earnings: What's in the Cards?
Zacks.com · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IRWD. Analyze the recent business situations of Ironwood Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IRWD stock price target is 13.17 with a high estimate of 20.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 294
Institutional Holdings: 182.50M
% Owned: 112.68%
Shares Outstanding: 161.97M
TypeInstitutionsShares
Increased
74
12.30M
New
37
5.02M
Decreased
65
11.32M
Sold Out
29
6.34M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
-0.06%
Key Executives
Chairman/Executive Director
Julie Mchugh
President/Chief Executive Officer/Director
Thomas McCourt
Chief Financial Officer/Chief Operating Officer/Senior Vice President
Jason Rickard
Senior Vice President
Michael Shetzline
Chief Accounting Officer/Controller
Ronald Silver
Director
Mark Currie
Independent Director
Alexander Denner
Independent Director
Andrew Dreyfus
Independent Director
Jon Duane
Independent Director
Marla Kessler
Independent Director
Catherine Moukheibir
Independent Director
Lawrence Olanoff
Independent Director
Edward Owens
Independent Director
Jay Shepard
No Data
  • All
  • Financials
  • Insiders
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Webull offers kinds of Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ:IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.